INTRODUCTION: Functional magnetic resonance imaging (fMRI) has been used extensively in an attempt to understand brain vulnerabilities that mediate maladaptive responses to drug cues. Using perfusion fMRI, we have consistently shown reward-related activation (medial orbitofrontal cortex/ventral striatum) to smoking cues (SCs). Because preclinical and clinical studies generally show that progesterone may reduce reward and craving, we hypothesized that females in the follicular phase of the cycle (FPs; when progesterone levels are low) would have greater reward-related neural responses to SCs compared with females in the luteal phase (LPs). METHODS: Sated cigarette-dependent premenopausal naturally cycling females underwent pseudo-continuous arterial spin-labeled perfusion fMRI during exposure to 10-min audio visual clips of appetitive SCs and non-SCs. Brain responses to SCs relative to non-SCs were examined among females grouped according to menstrual cycle (MC) phase at the time of scanning (22 FPs, 15 LPs). Craving scores were acquired pre- and post-SC exposure. RESULTS: FPs showed increased neural responses to SCs compared with non-SCs in the medial orbitofrontal cortex (p ≤ .05 corrected), whereas LPs did not. FPs reported SC-elicited craving (p ≤ .005), whereas LPs did not. Within FPs, SC-induced craving correlated with increased neural responses in the anterior insula (r = 0.73, p < .0001). CONCLUSIONS: FPs may be more vulnerable to relapse during appetitive SC exposure than LPs. Because the influence of MC phase on drug cue neural activity has not been examined, these results contribute to our knowledge of the neurobiological underpinnings of responses to drug cues, and they highlight the importance of monitoring menstrual cycle phase in all areas of addiction research.
INTRODUCTION: Functional magnetic resonance imaging (fMRI) has been used extensively in an attempt to understand brain vulnerabilities that mediate maladaptive responses to drug cues. Using perfusion fMRI, we have consistently shown reward-related activation (medial orbitofrontal cortex/ventral striatum) to smoking cues (SCs). Because preclinical and clinical studies generally show that progesterone may reduce reward and craving, we hypothesized that females in the follicular phase of the cycle (FPs; when progesterone levels are low) would have greater reward-related neural responses to SCs compared with females in the luteal phase (LPs). METHODS: Sated cigarette-dependent premenopausal naturally cycling females underwent pseudo-continuous arterial spin-labeled perfusion fMRI during exposure to 10-min audio visual clips of appetitive SCs and non-SCs. Brain responses to SCs relative to non-SCs were examined among females grouped according to menstrual cycle (MC) phase at the time of scanning (22 FPs, 15 LPs). Craving scores were acquired pre- and post-SC exposure. RESULTS: FPs showed increased neural responses to SCs compared with non-SCs in the medial orbitofrontal cortex (p ≤ .05 corrected), whereas LPs did not. FPs reported SC-elicited craving (p ≤ .005), whereas LPs did not. Within FPs, SC-induced craving correlated with increased neural responses in the anterior insula (r = 0.73, p < .0001). CONCLUSIONS: FPs may be more vulnerable to relapse during appetitive SC exposure than LPs. Because the influence of MC phase on drug cue neural activity has not been examined, these results contribute to our knowledge of the neurobiological underpinnings of responses to drug cues, and they highlight the importance of monitoring menstrual cycle phase in all areas of addiction research.
Authors: E C Donny; A R Caggiula; P P Rowell; M A Gharib; V Maldovan; S Booth; M M Mielke; A Hoffman; S McCallum Journal: Psychopharmacology (Berl) Date: 2000-09 Impact factor: 4.530
Authors: Nadia Chaudhri; Anthony R Caggiula; Eric C Donny; Sheri Booth; Maysa A Gharib; Laure A Craven; Shannon S Allen; Alan F Sved; Kenneth A Perkins Journal: Psychopharmacology (Berl) Date: 2005-01-29 Impact factor: 4.530
Authors: Eric D Claus; Sara K Blaine; Francesca M Filbey; Andrew R Mayer; Kent E Hutchison Journal: Neuropsychopharmacology Date: 2013-05-24 Impact factor: 7.853
Authors: Crystal Edler Schiller; Michael E Saladin; Kevin M Gray; Karen J Hartwell; Matthew J Carpenter Journal: Exp Clin Psychopharmacol Date: 2012-04-30 Impact factor: 3.157
Authors: Teresa R Franklin; Falk W Lohoff; Ze Wang; Nathan Sciortino; Derek Harper; Yin Li; Will Jens; Jeffrey Cruz; Kyle Kampman; Ron Ehrman; Wade Berrettini; John A Detre; Charles P O'Brien; Anna Rose Childress Journal: Neuropsychopharmacology Date: 2008-08-13 Impact factor: 7.853
Authors: Amy C Janes; Robert S Ross; Stacey Farmer; Blaise B Frederick; Lisa D Nickerson; Scott E Lukas; Chantal E Stern Journal: Addict Biol Date: 2013-11-22 Impact factor: 4.280
Authors: Kelly M Dumais; Teresa R Franklin; Kanchana Jagannathan; Nathan Hager; Michael Gawrysiak; Jennifer Betts; Stacey Farmer; Emily Guthier; Heather Pater; Amy C Janes; Reagan R Wetherill Journal: Drug Alcohol Depend Date: 2017-07-08 Impact factor: 4.492
Authors: Alicia M Allen; Andrea H Weinberger; Reagan R Wetherill; Carol L Howe; Sherry A McKee Journal: Nicotine Tob Res Date: 2019-04-17 Impact factor: 4.244
Authors: Nicole L Tosun; Ann M Fieberg; Lynn E Eberly; Katherine A Harrison; Angela R Tipp; Alicia M Allen; Sharon S Allen Journal: Addiction Date: 2019-06-17 Impact factor: 6.526
Authors: Shikha Prashad; Ryan P Hammonds; Amanda L Wiese; Amber L Milligan; Francesca M Filbey Journal: Drug Alcohol Depend Date: 2020-02-19 Impact factor: 4.492